Bladder urachal carcinoma
MONDO:0003715Urachal cancer is a type of bladder cancer, making up less than 1% of all bladder cancers. The urachus is a structure normally only present during development in the womb that connects the bellybutton and the bladder. This connection normally disappears before birth, but in some people remains. Urachalcancers are usually diagnosed in adults in their 50's and 60's and may develop at the dome or anterior wall of the bladder, along the midline of the body (including the belly button), and between the pubis symphasis and the bladder.Most urachal cancersare adenocarcinomas (cancers that develop from gland cells).Others may besarcomas (which develop from connective tissue -such as leiomyosarcoma, rhabdomyosarcoma, and malignant fibrous histiocytoma), small cell carcinomas, transitional cell cancer, and mixed neoplasias. Most individuals with urachal cancer have symptoms of with hematuria (blood in urine). Other symptoms may include abdominal pain, a palpable abdominal mass, mucinuria, and bacteriuria. Treatment usually involved surgery to remove the cancer.
Also known as: bladder urachal cancer, bladder urachal carcinoma, urachal carcinoma
2765 clinical trials for this condition and its sub-types, 3 tagged with Bladder urachal carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bladder urachal carcinoma
-
Bladder urachal adenocarcinoma 5 trials
-
Bladder urachal urothelial carcinoma 0 trials
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for hard-to-treat cancers: experimental drug targets HER2-positive tumors
Disease control Recruiting nowThis study tests a drug called trastuzumab rezetecan in people with advanced solid tumors that have stopped responding to standard therapies. The drug is given every three weeks to 90 participants divided into three groups based on their cancer type. Researchers will measure how …
Phase 2 • Sponsor: Sheng Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC